JP2020500015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500015A5 JP2020500015A5 JP2019522553A JP2019522553A JP2020500015A5 JP 2020500015 A5 JP2020500015 A5 JP 2020500015A5 JP 2019522553 A JP2019522553 A JP 2019522553A JP 2019522553 A JP2019522553 A JP 2019522553A JP 2020500015 A5 JP2020500015 A5 JP 2020500015A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- mhc class
- heterodimer
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 61
- 229920001184 polypeptide Polymers 0.000 claims 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims 60
- 239000000833 heterodimer Substances 0.000 claims 36
- 150000001413 amino acids Chemical class 0.000 claims 13
- 239000002105 nanoparticle Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 235000001014 amino acid Nutrition 0.000 claims 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- -1 cysteine amino acid Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000004811 liquid chromatography Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 101710120037 Toxin CcdB Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 235000014393 valine Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419947P | 2016-11-09 | 2016-11-09 | |
| US62/419,947 | 2016-11-09 | ||
| PCT/IB2017/001508 WO2018087597A1 (en) | 2016-11-09 | 2017-11-08 | Recombinant pmhc class ii molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500015A JP2020500015A (ja) | 2020-01-09 |
| JP2020500015A5 true JP2020500015A5 (enExample) | 2020-12-17 |
Family
ID=62065064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522553A Pending JP2020500015A (ja) | 2016-11-09 | 2017-11-08 | 組換えｐＭＨＣクラスＩＩ分子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180127481A1 (enExample) |
| EP (2) | EP4613336A3 (enExample) |
| JP (1) | JP2020500015A (enExample) |
| KR (2) | KR20240036138A (enExample) |
| CN (1) | CN110291111A (enExample) |
| AU (2) | AU2017357865B2 (enExample) |
| BR (1) | BR112019009477A2 (enExample) |
| CA (1) | CA3042615A1 (enExample) |
| CO (1) | CO2019004751A2 (enExample) |
| DK (1) | DK3538559T3 (enExample) |
| ES (1) | ES3035837T3 (enExample) |
| IL (1) | IL266391A (enExample) |
| MX (1) | MX2019005497A (enExample) |
| NZ (1) | NZ753596A (enExample) |
| SG (1) | SG10201913956RA (enExample) |
| WO (1) | WO2018087597A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| EP3065771B1 (en) | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
| BR112017023853A2 (pt) | 2015-05-06 | 2018-07-17 | Uti Limited Partnership | composições de nanopartícula para terapia sustentada. |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| AU2018234628B2 (en) | 2017-03-15 | 2023-07-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| US12397038B2 (en) | 2017-11-29 | 2025-08-26 | Uti Limited Partnership | Ubiquitous antigens for treatment of autoimmune or inflammatory diseases |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR20210071019A (ko) | 2018-10-05 | 2021-06-15 | 오레곤 헬스 앤드 사이언스 유니버시티 | 변형된 MHC 클래스 II DRα1 도메인을 포함하는 재조합 폴리펩타이드 및 이의 사용 방법 |
| WO2020181273A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| JP7691927B2 (ja) * | 2019-03-06 | 2025-06-12 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 |
| JP2022522405A (ja) * | 2019-03-06 | 2022-04-19 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| ES2974646T3 (es) * | 2019-08-09 | 2024-06-28 | Fraunhofer Ges Forschung | Complejos peptídicos HLA-DR/CII para el tratamiento de la artritis |
| WO2021035049A1 (en) * | 2019-08-21 | 2021-02-25 | Uti Limited Partnership | Improved recombinant pmhc molecules |
| EP4069722A1 (en) * | 2019-12-02 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| JP2025529913A (ja) * | 2022-08-26 | 2025-09-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラサイトカイン受容体及び使用方法 |
| WO2025021112A1 (zh) * | 2023-07-24 | 2025-01-30 | 佳吾益(北京)科技有限公司 | 开发mhc新抗原的工程化细胞 |
| WO2025111562A1 (en) * | 2023-11-22 | 2025-05-30 | Cue Biopharma, Inc. | Mhc class ii protein complexes |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE272070T1 (de) * | 1996-08-16 | 2004-08-15 | Harvard College | Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen |
| EP1094828A4 (en) | 1998-05-07 | 2005-01-26 | Univ California | USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| US20120083008A1 (en) * | 2004-07-06 | 2012-04-05 | Marshall Christopher P | Methods for obtaining molecules with reduced immunogenicity |
| US20140105980A1 (en) * | 2012-10-11 | 2014-04-17 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| CA2743590A1 (en) | 2008-11-12 | 2010-05-20 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
| GB201002730D0 (en) * | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
| WO2012121528A2 (en) * | 2011-03-04 | 2012-09-13 | Samsung Life Public Welfare Foundation | Magnetic nanocomposite specific for thyroid cancer and use thereof |
| US9603948B2 (en) * | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| US10501521B2 (en) * | 2012-12-21 | 2019-12-10 | Hoffmann-La Roche Inc. | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
| RU2612186C1 (ru) * | 2013-08-31 | 2017-03-02 | Халлибертон Энерджи Сервисез, Инк. | Устройство отклоняющего клина для бокового ствола скважины |
| EP3065771B1 (en) * | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
| KR102582035B1 (ko) * | 2014-12-24 | 2023-09-22 | 넥스이뮨, 인크. | 면역요법을 위한 나노입자 조성물 및 방법 |
| BR112017023853A2 (pt) * | 2015-05-06 | 2018-07-17 | Uti Limited Partnership | composições de nanopartícula para terapia sustentada. |
-
2017
- 2017-11-08 ES ES17870043T patent/ES3035837T3/es active Active
- 2017-11-08 NZ NZ753596A patent/NZ753596A/en unknown
- 2017-11-08 WO PCT/IB2017/001508 patent/WO2018087597A1/en not_active Ceased
- 2017-11-08 MX MX2019005497A patent/MX2019005497A/es unknown
- 2017-11-08 BR BR112019009477A patent/BR112019009477A2/pt unknown
- 2017-11-08 CN CN201780082781.5A patent/CN110291111A/zh active Pending
- 2017-11-08 KR KR1020247007677A patent/KR20240036138A/ko active Pending
- 2017-11-08 DK DK17870043.1T patent/DK3538559T3/da active
- 2017-11-08 SG SG10201913956RA patent/SG10201913956RA/en unknown
- 2017-11-08 EP EP25163642.9A patent/EP4613336A3/en active Pending
- 2017-11-08 AU AU2017357865A patent/AU2017357865B2/en active Active
- 2017-11-08 EP EP17870043.1A patent/EP3538559B1/en active Active
- 2017-11-08 US US15/807,415 patent/US20180127481A1/en not_active Abandoned
- 2017-11-08 JP JP2019522553A patent/JP2020500015A/ja active Pending
- 2017-11-08 KR KR1020197016386A patent/KR102646495B1/ko active Active
- 2017-11-08 CA CA3042615A patent/CA3042615A1/en active Pending
-
2019
- 2019-05-01 IL IL266391A patent/IL266391A/en unknown
- 2019-05-09 CO CONC2019/0004751A patent/CO2019004751A2/es unknown
-
2024
- 2024-08-20 US US18/810,261 patent/US20250051420A1/en active Pending
-
2025
- 2025-01-30 AU AU2025200608A patent/AU2025200608A1/en active Pending